Detalhe da pesquisa
1.
Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells.
J Cell Sci
; 136(19)2023 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37701987
2.
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Cancer Immunol Immunother
; 73(1): 17, 2024 Jan 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38236249
3.
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 41(3): 380-390, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-37040046
4.
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Gastroenterology
; 160(6): 2119-2132.e9, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33524400
5.
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma.
Gut
; 70(10): 1894-1903, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32933947
6.
Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma.
Int J Cancer
; 148(2): 481-491, 2021 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32955725
7.
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Oncologist
; 26(1): 7-16, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32852072
8.
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer.
J Oncol Pharm Pract
; 27(6): 1371-1381, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-32847480
9.
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
Br J Cancer
; 122(8): 1158-1165, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32147671
10.
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
Gastroenterology
; 157(3): 823-837, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31078621
11.
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
Invest New Drugs
; 38(5): 1601-1604, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31907737
12.
Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
BMC Cancer
; 17(1): 618, 2017 Sep 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28870260
13.
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCIâ¯9041).
Invest New Drugs
; 34(1): 104-11, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26686201
14.
Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Support Care Cancer
; 24(2): 799-805, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26184500
15.
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Carcinogenesis
; 36(9): 956-62, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26014353
16.
Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Cancer
; 121(4): 527-34, 2015 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25332117
17.
Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
Mod Pathol
; 28(10): 1383-9, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26226846
18.
Diagnostic value of next-generation sequencing in an unusual sphenoid tumor.
Oncologist
; 19(6): 623-30, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24807916
19.
Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients.
Ann Surg Oncol
; 21(12): 3917-23, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24859937
20.
Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.
Clin Cancer Res
; 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38727700